Research

Area 2

Applied research in infectious respiratory diseases, critically ill patients and lung cancer.

Team leader

Strategic objectives

  1. Study of community-acquired respiratory infections, nosocomial infections and infections in immune depressed patients.
  2. Study of invasive and noninasive mechanical ventilation in acute respiratory failure, particularly in weaning from artificial ventilation.
  3. Study of the exacerbation of chronic obstructive pulmonary disease (COPD) and the implication of bacterial, viral and fungal infectious agents.
  4. Physiopathological and treatment studies in an animal model of ventilation associated pneumonia.
  5. Human and animal model research in sleep apnea syndrome.
    6. Multicenter studies in relation to sleep respiratory pathology and cardiovascular disease.
  6. Epidemiology, diagnosis and treatment of adult bronchiectasia not associated with cystic fibrosis: Study of inflammatory response, new treatment modalities and immunoglobulin replacement therapy.

Main lines of research

  1. Epidemiology, prevention, diagnosis and new treatmentsof pneumonias associated with artificial ventilation. Resistances of microorganisms. Study of biofilms in endotracheal tubes.
  2. Epidemiology and diagnosis of community-acquired pneumonia. Multicenter studies in the setting of community-acquired pneumonia. New treatments. Resistances of microorganisms.
  3. Study of the risk factors, microbiology and prognosis of Health Care Associated Pneumonia (HCAP).
  4. Etiopathogenesis, bronchial infection and inflammation in the patient with chronic obstructive pulmonary disease (COPD). Role of infections in exacerbation of the disease. Study of bronchial and associated systemic response. Analysis of the risk and prognostic factors in acute episodes. Smoking. Epidemiology and diagnosis of alpha-1-antitrypsin deficiency.
  5. Chronic pulmonary infections: bronchiectasia not associated with cystic fibrosis, immune deficiencies and cystic fibrosis in the adult. Control of bronchial colonization. Study of bronchial inflammatory and associated systemic response. New treatment modalities (nebulizer antibiotic treatment). Replacement therapy with immunoglobulins.
  6. Infectious lung complications in immune depressed patients. Evaluation of the etiological factors. Optimization of the diagnostic techniques. Study of bronchial inflammatory and associated systemic response. Analysis of prognostic factors.
  7. Invasive and noninvasive mechanical ventilation: epidemiology, cost-effectiveness and physiopathology. New techniques. Weaning from mechanical ventilation: role of the inflammatory response and respiratory failure following extubation.
  8. Study of the pharmacokinetics of antibiotics and other drugs in the ventilated and non-ventilated patient.
  9. Porcine model of acute pulmonary damage due to P. aeruginosa and methicillin-resistant S. aureus: study of new coadjuvant drugs in the treatment of pneumonia, study of new antibiotics, prevention of ventilator-associated pneumonia (VAP), and new forms of mechanical ventilation.
  10. Chronic sleep apnea models.
  11. European studies of respiratory infections. Participation in the GRACE, MOSAR and THERAEDGE projects, which respectively investigate community-acquired respiratory infections, in-hospital respiratory infections and new diagnostic methods.

Grups

Breathing disturbances in sleep (Associated)

MONTSERRAT, JOSEP M.

(ICT)

The main research line of this group is the analysis of respiratory disturbances in sleep. Specifically, the two most important lines are the following: the study of diagnostic methods and effects of treatment in a population of apneic patients in which the indication is not clear; and the study of animal models for exploring the mechanisms underlying the origin and consequences of the disorder. Both lines are carried out in the context of national multicenter clinical trials.